28 Aug 2012, BioSpectrum Bureau , BioSpectrum
Ahmedabad: Claris Lifesciences has strategized to sell in the US after the approval from FDA. The company clarified that it no longer wishes to pursure its strategy to supply to the US through any of its partners including, Pfizer, West-ward and Sagent.
Following the recall of the deal, Pfizer and Claris had reviewed the supply agreement in wake of the import alert and the warning letter and the supply agreement with Pfizer is terminated. Prior to partnering with other companies, Claris had been selling in the US through its wholly owned subsidiary, Claris Lifesciences Incorporated. The subsidiary had developed adequate capabilities to sell on its own.
The company is confident of selling on own its own in the US and this strategy could be beneficial for the growth of the company as the pricing of products under the direct sale would be better than the supply through partners.